14.06.2012 - Italian neuroscience specialist Newron Pharmaceuticals S.p.A. acquires the Stockholm-based Neuronova AB in a deal worth €15.4m
Bresso/Stockholm – The transaction will add two new Phase II compounds from NeuroNova to Newron’s CNS portfolio. sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease (PD) that is designed to act on neural stem and progenitor cells in the brain. In a Phase I/II trial in patients with PD, the active ingredient platelet-derived growth factor BB demonstrated preliminary beneficial effects on biochemical markers of the degenerating dopamine system in PD patients. The second compound, sNN0029 with the active ingredient vascular endothelial growth factor, is intended for the treatment of amyotrophic lateral sclerosis (ALS) and is currently evaluated in a Phase I/II trial.
At the transaction close, Newron will benefit by cash and commitments of up to €16m. These funds are sufficient to provide for a Phase II study in PD as well as the ongoing Phase I/II study in ALS, in addition to the related corporate operations. The biggest investors in Neuronova, Investor and Healthcap, will also take a stake in Newron. Both will send a representative to the Milan-based company’s board of directors. At closing of the deal, the Neuronova shareholders will represent a holding of 33% in Newron’s share capital. For them, the transaction is a bid on the positive development of NeuroNova’s compounds. “We value Newron’s expertise in taking compounds from clinical stages to regulatory filing, and support the concept of building a European CNS player that could benefit both patients and our stakeholders”, stated Jakob Lindberg from Investor. “It is the logical next step to NeuroNova to combine our advanced pipeline and know-how, originally stemming from research at Karolinska Institute and developed by our team in the recent years, with a larger player in the CNS field”, added Ulf Ljungberg, President and CEO of NeuroNova, stating that the combined product portfolio represents “a strong platform on which to build the critical mass this industry is looking for.”
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.